

Commentary

Trust and Trade: Patient Perspectives on the Ethics of Real-World Data Monetisation

Alexandros Sagkriotis¹

1. Independent Consultant in Real-World Evidence and Health Data Science, United Kingdom

Real-world data (RWD) and real-world evidence (RWE) are now central to healthcare decision-making, supporting regulatory submissions, health technology assessments (HTA), and scientific communication. Yet patients whose data fuel these processes rarely see transparency or benefit when their information is commercialised. Governance frameworks from the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), and other bodies emphasise methodological rigor and transparency, but they seldom address fairness, reciprocity, or perceptions of legitimacy from a patient perspective.

This commentary argues that evidence integrity must extend beyond technical standards to encompass ethical stewardship. Drawing on case examples from the UK, EU, and North America, it shows how opacity in consent processes, selective disclosure of data use, and absence of benefit-sharing widen the trust gap. Patients contribute information under the assumption it will improve care, not simply generate commercial value or institutional advantage.

To address this, five pragmatic safeguards are proposed: (i) transparent, plain-language consent; (ii) mandatory disclosure of monetisation models; (iii) governance boards with patient representation; (iv) reinvestment of commercial gains into patient support, public health, and digital tools; and (v) mandatory registration of non-interventional studies in public registries. Together, these measures extend evidence integrity to include fairness, reciprocity, and legitimacy.

The future of RWE depends not only on scientific validity but also on whether patients trust that their data are handled responsibly and ethically. Perhaps it is time to move beyond passive consent and towards a new call for accountability—captured in a simple but powerful reminder: “*That is MY DATA.*” This commentary is informed by principles of relational ethics and the *social responsibility of science*, framing data monetisation as both a technical and moral question of reciprocity and legitimacy.

Introduction

Real-world data (RWD) are firmly embedded in regulatory science and health policy, with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) formally recognising real-world evidence (RWE) as a key element across the product lifecycle ^{[1][2]}. The Data Analysis and Real World Interrogation Network in the European Union (DARWIN EU) exemplifies the move from principles to execution by routinely generating regulator-led studies across Europe ^[3]. Yet these frameworks prioritise methodological adequacy and transparency; they do not meaningfully adjudicate the fairness of monetised secondary use from a patient's point of view.

Concurrently, the European Health Data Space (EHDS) introduces a legal infrastructure for the primary and secondary use of electronic health data (in force from March 26, 2025), explicitly enabling reuse for research and policy while strengthening individual control ^[4]. This represents a pivotal opportunity to align governance with public expectations around trust and benefit-sharing.

This paper does not attempt to re-evaluate the methodological standards already established for RWE. Instead, it asks a more fundamental set of questions:

- How do current regulatory and health technology assessment (HTA) frameworks address—or fail to address—the fairness of secondary use and monetisation of RWD?
- To what extent are patients informed about, and comfortable with, their data being transformed into economic value for institutions, companies, or individual careers?
- What safeguards could strengthen trust, reciprocity, and legitimacy in the secondary use of health data?

The objective is to extend the concept of evidence integrity beyond methodological rigor, arguing that patients' trust and perceptions of fairness must be central to the future credibility of RWE.

From a theoretical standpoint, this paper draws on *relational ethics*—which emphasises reciprocity and interdependence between data contributors and data users—and on the *social responsibility of science*, which situates evidence generation within collective obligations toward public good and democratic participation. These frameworks guide the interpretation of trust, fairness, and legitimacy throughout the paper.

What current frameworks cover—and what they miss

Regulatory and HTA-related guidance has matured rapidly: STaRT-RWE standardises protocol transparency ^[5]; HARPER provides a harmonised protocol template ^[6]; and the EUnetHTA REQueST tool articulates registry quality criteria ^[7]. These instruments sharpen scientific validity and reporting, but they are agnostic about who benefits economically from secondary use and how that is disclosed to patients.

FDA's RWE framework and its 2025 program updates reiterate definitions and decision contexts for using RWD in approvals and labelling changes—again, squarely methodological. The result is a governance landscape that improves science but leaves the ethics of monetisation and reciprocity largely to institutional policies and contracts ^[2].

The patient trust gap

Survey work in the United Kingdom (UK) consistently shows high trust in the National Health System (NHS) as a steward of data, but markedly lower trust in pharmaceutical and technology companies. In 2024, NHS Digital reported 72–83% trust in the NHS to keep data secure; curated evidence reviews from Understanding Patient Data (2021–2024) similarly document both broad support for data use and persistent unfamiliarity with secondary uses. Public preference skews towards de-identified data and transparency about purpose ^[8].

Findings from a 2024 systematic review show that public discomfort with commercial access remains high, especially when data are used for marketing or insurance purposes. The review also highlights that willingness to share for third-party uses hinges on trust, perceived public benefit, and clear safeguards ^[9]. Earlier UK surveys confirm these trends, with NHS stewardship trusted far more than corporate actors ^[8].

Global consumer research echoes this. Deloitte's 2024–2025 surveys find rising scepticism toward generative AI in health contexts, driven by distrust in outputs and unease about data handling—signals that any monetised data ecosystem must take seriously ^[10].

Case illustrations: when opacity erodes legitimacy

While both the DeepMind–Royal Free and NHS data platform debates reveal governance fragility, the DeepMind case illustrates in detail how the absence of early engagement erodes legitimacy. Analysing this case through the lens of *relational ethics* clarifies that the failure was not merely procedural but relational—patients were treated as data sources rather than moral partners.

DeepMind–Royal Free (UK): In 2017 the UK Information Commissioner’s Office concluded that Royal Free NHS Foundation Trust failed to comply with data protection law in sharing 1.6 million patient records with Google’s DeepMind to develop and test the Streams app, citing inadequate patient information. The episode is now a canonical example of “legal-process first, engagement later” and its reputational cost ^[11].

NHS national data platform and pricing debates: In parallel with NHS England’s Federated Data Platform build-out, policy discussions have explored a national health data service and pricing structures to recover costs of access. Editorials warn that perceived private profit from NHS data could undermine trust without visible public benefit and transparency ^[12].

Both cases illustrate what happens when public data are treated primarily as assets rather than as contributions from individuals — people who may rightfully feel, ‘this is my data,’ yet are rarely consulted on its use.

Monetisation: ethics and economics

Health systems, electronic health record (EHR) vendors, and third-party platforms increasingly treat de-identified data as an asset class. Recent scholarship documents data collection and commercialisation practices in primary care record industries, and ethics papers debate whether and when for-profit secondary use of publicly generated data is acceptable. Publics tend to support research-oriented reuse with clear public benefit, but react negatively to opaque commercial models ^[13].

In the UK, British Medical Journal (BMJ) commentary has cautioned against “selling NHS patient data” without clear benefit-sharing and transparent governance—again reflecting a legitimacy rather than a pure privacy concern ^[14]. The National Data Guardian’s 2023–24 report similarly centres “demonstrably trustworthy” use as essential to public confidence ^[15].

Viewed through *social responsibility ethics*, the monetisation of health data raises questions not of ownership alone but of distributive justice—who benefits, and who bears the moral cost of data extraction.

From method to meaning: expanding “evidence integrity”

Scientific transparency tools (STaRT-RWE, HARPER, REQueST) should be complemented by trust-building practices that speak to meaning for contributors: who profits, who governs, and who benefits. Absent this, even lawful, de-identified reuse may fail the legitimacy test—especially at scale or when private actors are central ^[16]. Further discussion of secondary use under the European Health Data Space (EHDS) and privacy-enhancing technologies is provided by van Drumpt et al. ^[17].

Five pragmatic safeguards

Building on the legitimacy principles outlined above, the following five safeguards operationalise *relational ethics* and the *social responsibility of science* in practice. They translate fairness, reciprocity, and accountability into concrete governance mechanisms that extend beyond compliance.

1. **Plain-language, layered consent (or notification) for secondary uses.** Consent materials should explain what kinds of secondary use and monetisation exist, by whom, and with what controls, aligned to EHDS guardrails and national opt-out regimes ^[4].
2. **Mandatory disclosure of monetisation models.** Public registries of data access agreements (who accessed, for what, value exchanged) would normalise transparency and enable audit—akin to trial registration for methods ^[18].
3. **Governance with patient representation.** Data access boards for secondary use should include trained patient/public members with real voting rights. This is consistent with the National Data Guardian’s emphasis on “demonstrably trustworthy” use ^[15].
4. **Visible benefit-sharing.** Where commercial value is created from public data, a defined proportion should be reinvested into patient support, patient associations, public health, digital tools, or the data infrastructure itself. Ongoing UK work on pricing/cost-recovery shows how models can be designed to avoid perceptions of “selling” while still covering costs ^[12].
5. **Protocol registration and transparency.** All non-interventional studies using patient data—whether for HTA, regulatory submissions, or scientific communication—should be registered in

publicly accessible databases such as the EU PAS Register, ClinicalTrials.gov, or ENCePP ^{[19][20][21]}. Registration of objectives, endpoints, and analysis plans creates a transparent record that reduces selective reporting, clarifies intent, and enhances accountability. This expectation should extend to both submission-grade and non-submission RWE, ensuring that the use of patient data is always visible and auditable ^{[22][23]}.

Together, these steps do not supplant methodological standards; they expand the meaning of “evidence integrity” to include fairness, reciprocity, and legitimacy—anchoring ethical trust as a measurable dimension of scientific quality.

Legitimate secondary uses

Access by industry to patient-level data for purposes such as HTA submissions, regulatory evidence generation, and peer-reviewed scientific communication should be regarded as legitimate and essential. These activities contribute to transparency in decision-making, accelerate patient access to innovative therapies, and improve clinical practice.

However, legitimacy requires that such uses are conducted within the same framework of safeguards: plain-language consent, disclosure of access agreements, patient-inclusive governance, visible benefit-sharing, and mandatory registration of protocols in publicly accessible registries such as the EU PAS Register, ClinicalTrials.gov, or ENCePP. Without these guardrails, even necessary evidence generation risks being perceived as exploitation rather than collaboration.

These legitimate uses set the ethical boundary conditions for the five safeguards proposed below.

Discussion

The analysis presented here highlights a structural blind spot in the governance of RWE. Regulatory and HTA frameworks have succeeded in advancing methodological rigor, transparency, and data quality, but they remain silent on fairness, reciprocity, and benefit-sharing. Surveys and case studies show that while patients broadly support data use for public benefit, they are consistently uneasy about opaque commercial access and monetisation. This trust gap poses a risk not only to the legitimacy of individual initiatives but to the credibility of RWE as a scientific field.

At its core, this blind spot reflects a tension between methodological integrity—how well evidence is generated—and relational integrity—how fairly data relationships are governed. *Relational ethics* provides

a lens through which this imbalance can be addressed. It frames patients not as passive data sources but as moral agents who participate in a continuous exchange of trust, expectation, and accountability. From this perspective, transparency is not a bureaucratic checkbox but an act of recognition and respect, and consent becomes an ongoing dialogue rather than a one-time procedural formality.

The DeepMind–Royal Free case serves as a vivid example of what happens when these relational dimensions are ignored. Despite legal authorisation, the absence of patient engagement created a perception of data extraction rather than partnership. Reinterpreting such cases through *relational ethics* suggests that failures in legitimacy are rarely technical—they are relational, arising when institutions treat data ownership as property instead of stewardship. Rebuilding this moral relationship requires new norms of dialogue, reciprocity, and visible accountability.

The *social responsibility of science* extends this reasoning from the interpersonal to the societal level. Scientific and commercial actors alike benefit from a social licence granted by citizens who share data in good faith. That licence carries duties: to reinvest value into patient communities, to democratise access to insights derived from shared data, and to ensure that monetisation does not become exploitation. Reinvestment in public infrastructure, open methods, and digital literacy programmes are therefore not peripheral acts of goodwill but expressions of moral reciprocity ^{[24][25]}. The proposed safeguards operationalise these duties in practical terms.

The safeguards proposed—transparent consent, disclosure of monetisation, patient representation in governance, visible benefit-sharing, and mandatory protocol registration—are not aspirational ideals but practical steps already mirrored in related domains, from trial registration to public involvement in research ethics. Each safeguard reflects a dimension of relational or social ethics in action: plain-language consent fosters informed participation; disclosure of monetisation makes visible the economic flows underpinning evidence generation; governance with patient representation redistributes epistemic authority; visible benefit-sharing acknowledges the collective origins of data value; and protocol registration transforms accountability into a traceable public record. Together, these measures link ethical theory to institutional design.

Beyond formal governance, legitimacy also depends on narrative coherence—the stories institutions tell about why and how data are used. Public trust is sustained not only by compliance but by shared meaning. When narratives emphasise partnership, reciprocity, and societal value, they generate alignment; when they focus narrowly on efficiency or profit, they breed scepticism. Embedding narrative

transparency into institutional communication—through patient-facing dashboards, co-created public reports, or community advisory panels—can transform technical openness into moral credibility ^{[26][27]}.

The European Health Data Space (EHDS) now offers a historic opportunity to embed these relational and social dimensions at scale. By linking cross-border health data, EHDS can enable transformative public health insights, but without deliberate attention to fairness and reciprocity, it risks amplifying the very inequities it seeks to overcome. The success of EHDS will therefore hinge on whether its implementation includes patient representation in governance boards, clarity around data valuation, and reinvestment mechanisms that channel benefits back to citizens.

Embedding these five safeguards into RWE practice would extend the concept of evidence integrity from methodological adequacy to social legitimacy. This reframing redefines “high-quality evidence” as data that are not only accurate and reproducible but also ethically sourced, transparently governed, and socially reciprocated. In that sense, RWE’s future credibility will depend as much on the fairness of its data relationships as on the rigour of its statistics. Only by uniting these two dimensions—scientific validity and moral legitimacy—can the promise of real-world data be realised in full.

Conclusion

RWE cannot thrive on methodological excellence alone. Patients’ willingness to share—and society’s mandate to use—rests on trust that secondary uses (including monetised ones) are transparent, fairly governed, and deliver visible public benefit. With EHDS now in force and global transparency tools maturing, the moment is ripe to embed reciprocity into the RWE ecosystem.

The five safeguards outlined in this commentary—plain-language consent, disclosure of monetisation models, governance with patient representation, visible benefit-sharing, and mandatory protocol registration—provide a feasible framework to achieve this.

Fair governance of real-world data is therefore not merely a regulatory aspiration but a moral contract grounded in *relational ethics* and the *social responsibility of science*. As data ecosystems grow more interconnected, the legitimacy of RWE will depend as much on relational integrity as on analytical precision. Building mechanisms for dialogue, transparency, and visible benefit-sharing can convert data contribution from an act of compliance into one of trust and shared purpose.

The future of RWE will ultimately be measured not only by the robustness of its methods, but by the fairness of its relationships—with patients, with publics, and with the systems that rely on their

information.

Perhaps it is time to move beyond passive consent and towards a new call for accountability—one that could be captured in a simple but powerful reminder: “That is MY DATA.”

Statements and Declarations

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of Interest

The author declares no competing interests. The views expressed are those of the author and do not necessarily reflect the positions of past or current affiliations.

Grant Information

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contributions

AS is the sole author of this policy brief and is responsible for conceptualisation, drafting, and final approval of the manuscript.

Acknowledgements

The author wishes to thank his daughter for her encouragement and inspiration, which have been a constant reminder of the importance of striving for a fairer and more evidence-informed healthcare future. With over 30 years of experience in senior leadership roles across global pharmaceutical companies—spanning clinical development, real-world evidence, and medical affairs—the author has drawn on both professional expertise and personal reflections to write this commentary. Portions of the manuscript, including language refinement and structural suggestions, were supported using OpenAI’s ChatGPT-5 model. The author critically reviewed, edited, and validated all content to ensure accuracy, originality, and alignment with scholarly standards.

The author gratefully acknowledges the anonymous peer reviewer for valuable feedback that helped refine the conceptual framing, strengthen theoretical underpinnings, and improve readability of the manuscript.

References

1. [△]European Medicines Agency (2025). "Real-World Evidence (RWE)." EMA. <https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence>.
2. [△][△]U.S. Food and Drug Administration (2018). "Framework for FDA's Real-World Evidence Program." FDA. <https://www.fda.gov/media/120060/download>.
3. [△]DARWIN EU (2025). "About DARWIN EU." DARWIN EU. <https://www.darwin-eu.org/>.
4. [△][△]European Commission, Council of the European Union (2025). "European Health Data Space Regulation Adopted." European Commission. https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space-regulation-ehds_en.
5. [△]Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA, et al. (2021). "STaRT-RWE: Structured Template for Planning and Reporting on the Implementation of Real World Evidence Studies." *BMJ*. 372:m4856. doi:10.1136/bmj.m4856.
6. [△]Wang SV, Pottegård A, Crown W, Arlett P, Ashcroft DM, Benchimol EI, et al. (2022). "HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force." *Pharmacoepidemiol Drug Saf*. 31(10):1068–1079. doi:10.1002/pds.5507. PMID 36213854.
7. [△]European Network for Health Technology Assessment (EUnetHTA) (2023). "Registry Evaluation and Quality Standards Tool (REQueST)." European Medicines Agency catalogues. [https://catalogues.ema.europa.eu/system/files/2025-02/05.01.0301%20Feasibility%20Documentation%20%20-%20Registry%20Evaluation%20and%20Quality%20Standards%20Tool%20%28REQueST%29%20%2010-Sep-2023 Redacted.pdf](https://catalogues.ema.europa.eu/system/files/2025-02/05.01.0301%20Feasibility%20Documentation%20%20-%20Registry%20Evaluation%20and%20Quality%20Standards%20Tool%20%28REQueST%29%20%2010-Sep-2023%20Redacted.pdf).
8. [△][△]NHS England, NHS Digital (2024). "Public Attitudes to Data in the NHS and Social Care." NHS Digital. <https://digital.nhs.uk/data-and-information/keeping-data-safe-and-benefitting-the-public/public-attitudes-to-data-in-the-nhs-and-social-care>.
9. [△]Ipsos MORI (2017). "The One-Way Mirror: Public Attitudes to Commercial Access to Health Data." Wellcome Trust. doi:10.6084/m9.figshare.5616448.v1.

10. [△]Deloitte Insights (2024). "Consumer Trust in Healthcare Generative AI (2024) and 2025 Global Healthcare Outlook." Deloitte Insights. https://www.deloitte.com/us/en/insights/industry/health-care/consumer-trust-in-health-care-generative-ai.html?utm_source=chatgpt.com.
11. [△]ICO (UK) (2017). "DeepMind and Royal Free Case Resources (Patient Data Sharing Ruling)." National Health Executive. https://www.nationalhealthexecutive.com/Research-and-Technology/patient-data-transfer-to-google-deepmind-by-trust-deemed-unlawful-by-ico?utm_source=chatgpt.com.
12. ^{a, b}Financial Times (2024). "UK Studies Pricing Plan for Selling NHS Patient Data." Financial Times. https://www.ft.com/content/9ec787a8-60d5-4899-8223-81335dfa919b?utm_source=chatgpt.com.
13. [△]Spithoff S, McMahon M, Martin D, Golembeski S, Persaud N, Pinto AD, et al. (2025). "The Primary Care Medical Record Industry: Data Collection and Commercialization." *JAMA Netw Open*. 8(5):e257688. doi:[10.1001/jamanetworkopen.2025.7688](https://doi.org/10.1001/jamanetworkopen.2025.7688).
14. [△]Morley J, Hamilton N, Floridi L (2024). "Selling NHS Patient Data." *BMJ*. 384:q420. doi:[10.1136/bmj.q420](https://doi.org/10.1136/bmj.q420).
15. ^{a, b}National Data Guardian (UK) (2024). "Annual Report 2023–2024." Department of Health and Social Care. <https://www.gov.uk/government/publications/national-data-guardian-2023-2024-report/national-data-guardian-2023-2024-report>.
16. [△]Guilhaume C (2021). "A Tool to Assess the Registries Quality: The Registry Evaluation and Quality Standards Tool (REQueST)." *Eur J Public Health*. 31(Suppl 3):ckab164.573. doi:[10.1093/eurpub/ckab164.573](https://doi.org/10.1093/eurpub/ckab164.573).
17. [△]van Drumpt S, Chawla K, Barbereau T, Spagnuolo D, van de Burgwal L (2025). "Secondary Use Under the European Health Data Space: Setting the Scene and Towards a Research Agenda on Privacy-Enhancing Technologies." *Front Digit Health*. 7:1602101. doi:[10.3389/fdgth.2025.1602101](https://doi.org/10.3389/fdgth.2025.1602101). PMID [40613075](https://pubmed.ncbi.nlm.nih.gov/40613075/); PMCID [PMC1222193](https://pubmed.ncbi.nlm.nih.gov/PMC1222193/).
18. [△]International Society for Pharmacoeconomics and Outcomes Research (ISPOR), International Society for Pharmacoepidemiology (ISPE), Duke–Margolis Center for Health Policy, National Pharmaceutical Council (NPC) (2020). "Real-World Evidence Transparency Initiative." ISPOR. <https://www.ispor.org/strategic-initiatives/real-world-evidence/real-world-evidence-transparency-initiative>.
19. [△]European Medicines Agency (2025). "ENCePP: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance." EMA. <https://www.encepp.eu/>.
20. [△]European Medicines Agency (2025). "EU PAS Register: European Union Electronic Register of Post-Authorisation Studies." EMA. <https://www.encepp.eu/encepp/studiesDatabase.jsp>.
21. [△]U.S. National Library of Medicine (2025). "ClinicalTrials.gov." National Institutes of Health. <https://clinicaltrials.gov/>.

22. [△]Naudet F, Patel CJ, DeVito NJ, Le Goff G, Cristea IA, Braillon A, et al. (2024). "Improving the Transparency and Reliability of Observational Studies Through Registration." *BMJ*. **384**:e076123. doi:[10.1136/bmj-2023-076123](https://doi.org/10.1136/bmj-2023-076123).
23. [△]Council of the European Union (2025). "European Health Data Space: Council Adopts New Regulation Improving Cross-Border Access to EU Health Data." Council of the EU. <https://www.consilium.europa.eu/en/press/press-releases/2025/01/21/european-health-data-space-council-adopts-new-regulation-improving-cross-border-access-to-eu-health-data/>.
24. [△]Shaw E (2011). "Relational Ethics and Moral Imagination in Contemporary Systemic Practice." *Aust N Z J Fam Ther*. **32**(1):1–14. doi:[10.1375/anft.32.1.1](https://doi.org/10.1375/anft.32.1.1).
25. [△]Resnik DB (2016). "The Ethical Challenges of Socially Responsible Science." *Accountability Res*. **23**(2):89–102. doi:[10.1080/08989621.2014.1002608](https://doi.org/10.1080/08989621.2014.1002608).
26. [△]Floridi L, Taddeo M (2016). "What Is Data Ethics?" *Philos Trans A Math Phys Eng Sci*. **374**(2083):20160360. doi:[10.1098/rsta.2016.0360](https://doi.org/10.1098/rsta.2016.0360).
27. [△]Carter P, Laurie GT, Dixon-Woods M (2015). "The Social Licence for Research: Why Care.Data Ran Into Trouble." *J Med Ethics*. **41**(5):404–409. doi:[10.1136/medethics-2014-102374](https://doi.org/10.1136/medethics-2014-102374).

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.